Stephen LaMond
Directeur Général chez PEAK BIO, INC.
Fortune : 3 732 $ au 31/12/2023
Profil
Stephen J.
LaMond is currently the CEO, COO, Secretary & Director at Peak Bio, Inc. and also holds the position of Chief Operating Officer at Peak Bio Co. Ltd.
Previously, he worked as the Director of Business Development & Marketing at Nektar Therapeutics, Vice President of Business Development at Corium International, Inc., Vice President of Marketing & Business Development at Aridis Pharmaceuticals, Inc., and Team Leader at Pfizer NV.
He completed his undergraduate degree at the University of Michigan.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PEAK BIO, INC.
0,09% | 27/09/2023 | 19 850 ( 0,09% ) | 3 732 $ | 31/12/2023 |
Postes actifs de Stephen LaMond
| Sociétés | Poste | Début |
|---|---|---|
| PEAK BIO, INC. | Directeur Général | 01/11/2022 |
Peak Bio Co. Ltd.
 Peak Bio Co. Ltd. BiotechnologyHealth Technology Part of Peak Bio, Inc., Peak Bio Co. Ltd. is a South Korean clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and inflammation. Peak Bio's location is in Seongnam, South Korea. The company's lead product candidate, php-303, is a small molecule currently in phase II clinical study for the orphan disease alpha1 anti-trypsin deficiency. Peak Bio has successfully completed phase I trials, demonstrating dose-dependent pharmacokinetics and establishing a dose for upcoming clinical trials. The company's cancer platform includes novel payloads and antibody-drug-conjugates (ADC) to address unmet needs in cancer care. The company was founded in 2015, and the CEO is Ho Young Huh. Peak Bio Co. was acquired by Ignyte Acquisition Corp. on November 01, 2022 for $353.84 million. | Directeur des opérations | - |
Anciens postes connus de Stephen LaMond
| Sociétés | Poste | Fin |
|---|---|---|
| CORIUM INTERNATIONAL INC | Corporate Officer/Principal | - |
| NEKTAR THERAPEUTICS | Sales & Marketing | - |
| Pfizer NV/SA | Corporate Officer/Principal | - |
| ARIDIS PHARMACEUTICALS, INC. | Sales & Marketing | - |
Formation de Stephen LaMond
| University of Michigan | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| PEAK BIO, INC. | Health Technology |
| ARIDIS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Corium International, Inc.
 Corium International, Inc. Pharmaceuticals: MajorHealth Technology Corium International, Inc. is a pharmaceutical company. It offers products such as corplex donepezil and memantine. The company was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1999 and is headquartered in Menlo Park, CA. | Health Technology |
| Pfizer NV/SA | |
Peak Bio Co. Ltd.
Peak Bio Co. Ltd. BiotechnologyHealth Technology Part of Peak Bio, Inc., Peak Bio Co. Ltd. is a South Korean clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and inflammation. Peak Bio's location is in Seongnam, South Korea. The company's lead product candidate, php-303, is a small molecule currently in phase II clinical study for the orphan disease alpha1 anti-trypsin deficiency. Peak Bio has successfully completed phase I trials, demonstrating dose-dependent pharmacokinetics and establishing a dose for upcoming clinical trials. The company's cancer platform includes novel payloads and antibody-drug-conjugates (ADC) to address unmet needs in cancer care. The company was founded in 2015, and the CEO is Ho Young Huh. Peak Bio Co. was acquired by Ignyte Acquisition Corp. on November 01, 2022 for $353.84 million. | Health Technology |
